RNA

Part:BBa_K1942000:Experience

Designed by: Chai Yingzi, Chen Jingyi, Deng Chenghui, Gu Xiaoyang, Peng Yue   Group: iGEM16_NJU-China   (2016-10-10)
Revision as of 10:14, 13 October 2016 by I (Talk | contribs) (→‎USAGE AND BIOLOGY)


This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K1942000

USAGE AND BIOLOGY

We packaged KRAS siRNA into exosomes by transfecting HEK293 cells with a plasmid expressing KRAS siRNA and then collected siRNA-encapsulated exosomes. When modified exosomes being intravenously injected, they will specifically recognize integrin receptors and fuse with Lung adenocarcinoma cells under the direction of the iRGD peptide. Once inside cells, KRAS siRNA will bind to KRAS mRNA through base-pairing and digest the mRNA, resulting in sharp decrease of K-ras in lung cancer cells. As a consequence, K-ras protein’s reduction and disturbed function will both result in the inhabitation of the proliferation of cancer cells, which ultimately have some therapeutic effects on lung cancer (non-small cell lung cancer in this case).

NJU China 2016 iGEM Parts Description K1942000 Figure 2.png

Figure 1. Protein quantitatively analysis of K-ras protein after transfection of KRAS siRNA

CHARACTERIZATION

To ensure the interference efficiency of anti-KRAS siRNA plasmid, we transfected it into human Lung adenocarcinoma cell line A549 and then extracted protein to perform a western blotting. Significant downregulation of K-ras can be observed in A549 cells treating with anti-KRAS siRNA, demonstrating that anti-KRAS siRNA has a gene silencing effect on Lung cancer cells.

User Reviews

UNIQ701d2c7634541c9f-partinfo-00000000-QINU UNIQ701d2c7634541c9f-partinfo-00000001-QINU